ESMO 2022 | Long term survival data from the Phase III Keynote-054 trial

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, provides an overview of 5-year follow-up results from the Phase III EORTC 1325-MG/Keynote-054 trial (NCT02362594) of pembrolizumab in high-risk stage III melanoma. The practice-changing trial demonstrates the long-term efficacy of pembrolizumab, with high rates of relapse-free survival observed in the patient cohort. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.